Hela-Cas9 Cell (human cervical cancer cells)

Species: human
Cell Morphology: Adherent cells, epithelial-like
Complete Culture Medium Components: 1640+10%FBS
Mycoplasma testing: Negative
Antibiotic Concentration: puromycin, 0.5ug/ml
Cultivation Environment: 37°C, 5% CO₂
Passage Ratio: 1/2 to 1/4 of the generations
Frequency of Reproduction: 2-3 times/week
Gene Expression: Cas9 protein, spCas9, CRISPR-Cas9 protein

Product Advantages:
• Efficiency and Convenience: A "ready-to-use" platform; simply import gRNA, operation is simple, editing efficiency is high, saving time and costs.
• High-Throughput Screening: An ideal foundational platform for genome-wide CRISPR screening, used for systematic discovery of functional genes.
• Consistency and Reproducibility: Consistent cell population genetic background ensures stable Cas9 expression, resulting in more reliable experimental results and more rigorous control settings.
• Functional Scalability: Cell lines expressing dCas9, high-fidelity Cas9, and other variants can be constructed to achieve multiple functions beyond gene knockout (regulation, imaging, etc.).

Please contact us at for specific academic pricing.

Background

HeLa cells are the first continuously cultured and maintained aneuploid epithelioid cell line derived from human tissue. HeLa cells were established in 1951 by G.D. Gey et al. from cervical cancer in a 31-year-old Black woman. Upon re-examination of the original tissue sections, Jones et al. diagnosed it as adenocarcinoma. This cell line is known to contain the human papillomavirus 18 sequence and requires handling in a biosafety level 2 environment. HeLa cells are keratin-positive, have low p53 expression, but express normal levels of Prb (retinoblastoma suppressor factor).